Multidetector Computed Tomography to Facilitate Transcatheter Aortic Valve Implantation

被引：0
作者：
Leipsic J. [1 ,2 ]
Wood D.A. [2 ]
Gurvitch R. [2 ]
Hague C.J. [1 ]
机构：
[1] Department of Radiology, St. Paul's Hospital, University of British Columbia, Vancouver
[2] Division of Cardiology, Department of Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, BC, V6S 1Y6
来源：
Current Cardiovascular Imaging Reports | 2011年 / 4卷 / 6期
关键词：
Multidetector computed tomography; Transcatheter aortic valve replacement;
D O I：
10.1007/s12410-011-9106-4
中图分类号：
学科分类号：
摘要：
Minimally invasive balloon expandable transcatheter aortic valve replacement (TAVR) is currently the standard of care for patients with inoperable severe symptomatic aortic stenosis and is an acceptable alternative to traditional aortic valve replacement in selected high-risk operable patients. Multidetector computed tomography (MDCT) is an integral component of diagnostic workup prior to TAVR. We review the pivotal role of MDCT in patient selection by discussing pre-procedural assessment of iliofemoral, aortic root, and annular geometry. We summarize how MDCT can help guide percutaneous vascular access as well as accurately determine the correct co-axial valve plane and transcatheter valve size. Finally, we discuss how MDCT provides important information about long-term valve durability by assessing valve eccentricity, leaflet and stent integrity, valve recoil, and valve migration. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：457 / 467
页数：10
相关论文
共 35 条
[11]  
Smith C.R., on behalf of The PARTNER Trial Investigators. Transcatheter vs. Surgical aortic valve replacement in high risk patients with severe aortic stenosis: results from the PARTNER a trial, ACC New Orleans, (2011)
[12]  
Ye J., Cheung A., Lichtenstein S.V., Et al., Transapical aortic valve implantation in humans, J Thorac Cardiovasc Surg, 131, pp. 1194-1196, (2006)
[13]  
Grube E., Laborde J.C., Gerckens U., Et al., Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study, Circulation, 114, pp. 1616-1624, (2006)
[14]  
Al Ali A.M., Altwegg L., Horlick E.M., Et al., Prevention and management of transcatheter balloon-expandable aortic valve malposition, Catheter Cardiovasc Interv, 72, pp. 573-578, (2008)
[15]  
Tuzcu M.E., Transcatheter aortic valve replacement malposition and embolization: innovation brings solutions also new challenges, Catheter Cardiovasc Interv, 72, pp. 579-580, (2008)
[16]  
Thomas M., Schymik G., Walther T., Et al., Thirty-day results of the SAPIEN aortic bioprosthesis European outcome (SOURCE) registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve, Circulation, 122, 1, pp. 62-69, (2010)
[17]  
van Mieghem N.M., Nuis R.J., Piazza N., Et al., Vascular complications with transcatheter aortic valve implantation using the 18 Fr Medtronic CoreValve System(R): the Rotterdam experience, EuroIntervention, 5, pp. 673-679, (2010)
[18]  
Tchetche D., Dumonteil N., Sauguet A., Et al., Thirty-day outcome and vascular complications after transarterial aortic valve implantation using both Edwards Sapien and Medtronic CoreValve bioprostheses in a mixed population, EuroIntervention, 5, 6, pp. 659-665, (2010)
[19]  
Sharp A.S., Michev I., Maisano F., Et al., A new technique for vascular access management in transcatheter aortic valve implantation, Catheter Cardiovasc Interv, 75, 5, pp. 784-793, (2010)
[20]  
Leon M., Piazza N., Nikolsky E., Et al., Standardized endpoint definitions fortranscatheter aorticvalve implantation clinical trials: a consensus report from the Valve Academic Research Consortium, Jacc, 57, pp. 253-269, (2011)
1234